We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Rejects NDA for Atrial Fibrillation Treatment
Advisory Committee Rejects NDA for Atrial Fibrillation Treatment
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted eleven to two yesterday not to recommend approval of Correvio International’s NDA for vernakalant hydrochloride solution for treatment of recent onset atrial fibrillation.